Hypercoagulability in venous and arterial thrombosis

Annals of Internal Medicine

Volumn 126, Issue 8, 1997, Pages 638-644

  Thomas, Duncan P ^a   Roberts, Harold R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; PROTEIN C; PROTEIN S;

ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FIBRINOLYSIS; GENE MUTATION; HOMOCYSTINURIA; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0030893834     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-8-199704150-00009     Document Type: Article

References (51)

1. Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet. 1994;344:1739-42.
2. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A. 1994;91:1396-400.
3. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RH, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:14-5.
4. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995;85:607-14.
5. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995;74:139-48.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.
7. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost. 1995;74:580-3.
8. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031-5.
9. Samama MM, Trossaert M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients homozygous for factor V Leiden [Letter]. Blood. 1995;86:4700-2.
10. Bloemenkamp KW, Rosendaal FR, Heimerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet. 1995;346:1593-6.
11. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-3.
12. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-4.
13. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletkh JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
14. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction is not associated with the ARG 506 to GLN factor V mutation causing resistance to activated protein C. Thromb Haemost. 1995;73:1812.
15. Schroder W, Koessling M, Wulff K, Wehnert M, Herrmann FH. World distribution of factor V Leiden mutation [Letter]. Lancet. 1996;347:58-9.
16. Tosetto MB, Gatto E, Rodeghiero F. ACP resistance (Factor V Leiden) has a higher prevalence in females. Preliminary results from the Vicenza Thrombophilia and Arteriosclerosis (VITA) project. Thromb Haemost. 1995;73:1124.
17. Mannucci PM, Duca F, Peyvandi F, Tagliabue L, Merati G, Martinelli I, et al. Frequency of factor V Arg506 Gln in Italians [Letter]. Thromb Haemost. 1996;75:694
18. Pottinger P, Sigurdsson F, Berliner N. Detection of the factor V Leiden mutation in a nonselected black population [Letter]. Blood. 1996;87:2091.
19. Dahlback B, Stenflo J. A natural anticoagulant pathway: protein C, S, C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis. 3d ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. New York: Churchill Livingstone: 1994;671-98.
20. Lane DA, Olds RJ, Thein SL. Antithrombin and its deficiency. In: Haemostasis and Thrombosis. 3rd ed. Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. New York: Churchill Livingstone: 1994:655-70.
21. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-6.
22. Koster T, Rosendaal FR, Briet E, van de Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients, an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-61.
23. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987;317:991-6.
24. Allaart CF, Poort SW, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet. 1993;341:134-8.
25. Rosendaal FR, Heijboer H, Briet E, Buller HR, Brandjes DP, de Bruin K, et al. Mortality in hereditary antithrombin-III deficiency - 1830 to 1989. Lancet. 1991;337:260-2.
26. Allaart CF, Rosendaal FR, Noteboom WM, Vandenbroucke JP, Briet E. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ. 1995;311:910-3.
27. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;34:759-62.
28. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med. 1996;334:763-8.
29. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993;72:477-80.
30. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost. 1995;74:94-100.
31. Treatment of Venous Thrombosis and Pulmonary Embolism. Oslo: Lakemedelsverket; 1995.
32. Santoro SA. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms [Editorial]. Blood. 1994;83:2389-91.
33. Feinstein DI. Inhibitors of blood coagulation. In: Hematology: Basic Principles and Practice. 2d ed. Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, eds. New York: Churchill Livingstone; 1995:1746-53.
34. Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993;52:689-92.
35. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-4.
36. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-5.
37. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-7.
38. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183-6.
39. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J. 1995;16(Suppl A):31-4.
40. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-41.
41. Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease [Letter]. Lancet. 1987;2:461.
42. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJM 1994;87:403-6.
43. Miller GJ, Wilkes HC, Meade TW, Bauer KA, Barzegar S, Rosenberg RD. Haemostatic changes that constitute the hypercoagulable state [Letter]. Lancet. 1991;338:1079.
44. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996;75:767-71.
45. Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med. 1988;111:475-81.
46. Hultin MB. Fibrinogen and factor VII as risk factors in vascular disease. In: Progress in Hemostasis and Thrombosis. Coller BS, ed. Philadelphia: WB Saunders; 1991:215-41.
47. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734-44.
48. Morrissey JH. Plasma factor VIIa: measurement and potential clinical significance. Haemostasis. 1996;26(Suppl):66-71.
49. Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol. 1995;75:23B-6B.
50. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 1991;151:1721-31.
51. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost. 1995;74:71-6.